Anti-Human VEGF Reference Antibody (Aflibercept, RUO)
- Catalog number: BS10524
- Availability: In Stock
$424.00
- Ex Tax: $424.00
Description: Aflibercept (BS10524) is a research-grade recombinant antibody targeting Vascular endothelial growth factor A. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG1-Fc
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 2.37mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: VascularendothelialgrowthfactorA,VPF,VEGFA,VEGF,Vascularpermeabilityfactor,VEGF-A
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: CAS:862111-32-8
Background: Vascular endothelial growth factor A, long form (VEGFA) is a ~43 kDa protein. Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A. Involved in protecting cells from hypoxia-mediated cell death. VEGFA is the therapeutic target of bevacizumab (Avastin).
References:
1. Katsman, M. et al. (2022) Cells 11. PMID: 35455969
Note: For research use only. Not suitable for clinical or therapeutic use.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG1-Fc
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 2.37mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: VascularendothelialgrowthfactorA,VPF,VEGFA,VEGF,Vascularpermeabilityfactor,VEGF-A
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: CAS:862111-32-8
Background: Vascular endothelial growth factor A, long form (VEGFA) is a ~43 kDa protein. Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A. Involved in protecting cells from hypoxia-mediated cell death. VEGFA is the therapeutic target of bevacizumab (Avastin).
References:
1. Katsman, M. et al. (2022) Cells 11. PMID: 35455969
Note: For research use only. Not suitable for clinical or therapeutic use.
Images
-
SEC-HPLCSEC-HPLC detection for Research Grade Aflibercept.
-
SDS-PAGESDS-PAGE for Research Grade Aflibercept.
-
Flow CytoMetryFlow-cytometry using FITC anti-human VEGFA antibody. U87 cells were fixed and permeabilized, then stained with an irrelevant antibody (Blue Histogram) or an FITC anti-human VEGFA monoclonal antibody (Catalog: HB941296, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer.
